JO3581B1 - مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي - Google Patents
مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسوميInfo
- Publication number
- JO3581B1 JO3581B1 JOP/2015/0256A JOP20150256A JO3581B1 JO 3581 B1 JO3581 B1 JO 3581B1 JO P20150256 A JOP20150256 A JO P20150256A JO 3581 B1 JO3581 B1 JO 3581B1
- Authority
- JO
- Jordan
- Prior art keywords
- synthase
- compounds useful
- piperidine compounds
- microsomal prostaglandin
- novel methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
Abstract
يتعلق الاختراع الحالي بتوفير مركبات لها الصيغة 1، أو ملح مقبول صيدليًا منها، 1، حيث تكون R، R1، وG على النحو الموصوف هنا؛ طرق لتحضير المركبات؛ واستخدام المركبات لعلاج الألم و/أو الالتهاب المصاحب لالتهاب المفاصل أو الالتهاب العظمي المفصلي.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462072196P | 2014-10-29 | 2014-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3581B1 true JO3581B1 (ar) | 2020-07-05 |
Family
ID=54478248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2015/0256A JO3581B1 (ar) | 2014-10-29 | 2015-10-18 | مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي |
Country Status (26)
Country | Link |
---|---|
US (2) | US9962375B2 (ar) |
EP (1) | EP3230278B1 (ar) |
JP (1) | JP6393830B2 (ar) |
KR (1) | KR101898829B1 (ar) |
CN (1) | CN107074829B (ar) |
AR (1) | AR102362A1 (ar) |
AU (1) | AU2015339644B2 (ar) |
CA (1) | CA2963321C (ar) |
CL (1) | CL2017001017A1 (ar) |
CY (1) | CY1122534T1 (ar) |
DK (1) | DK3230278T3 (ar) |
EA (1) | EA032428B1 (ar) |
ES (1) | ES2773439T3 (ar) |
HR (1) | HRP20200216T1 (ar) |
HU (1) | HUE047895T2 (ar) |
JO (1) | JO3581B1 (ar) |
LT (1) | LT3230278T (ar) |
MX (1) | MX2017005659A (ar) |
NZ (1) | NZ730724A (ar) |
PL (1) | PL3230278T3 (ar) |
PT (1) | PT3230278T (ar) |
RS (1) | RS59783B1 (ar) |
SI (1) | SI3230278T1 (ar) |
TW (1) | TWI605039B (ar) |
WO (1) | WO2016069376A1 (ar) |
ZA (1) | ZA201702198B (ar) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR102361A1 (es) | 2014-10-29 | 2017-02-22 | Lilly Co Eli | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 |
CA3088151A1 (en) * | 2018-01-09 | 2019-07-18 | Brigham Young University | Compositions and methods for treating pain with wogonin |
CN108558806B (zh) * | 2018-05-31 | 2020-04-17 | 南京药石科技股份有限公司 | 一种5-氧代-四氢吡喃-3-羧酸酯的关键中间体及其制备方法 |
US20210346328A1 (en) * | 2018-09-21 | 2021-11-11 | The Johns Hopkins University | Compositions and methods for treating metabolic disorders |
CA3142513A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
JP2023509881A (ja) | 2019-12-24 | 2023-03-10 | カルナバイオサイエンス株式会社 | ジアシルグリセロールキナーゼ調節化合物 |
CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
EP4143194A1 (en) | 2020-05-01 | 2023-03-08 | Gilead Sciences, Inc. | Cd73 inhibiting 2,4-dioxopyrimidine compounds |
TW202211917A (zh) * | 2020-08-21 | 2022-04-01 | 南韓商治納輔醫藥科技有限公司 | 對前列腺素e2受體具有抑制活性的新穎化合物及其用途 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用FLT3L—Fc融合蛋白之方法 |
US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
TW202330504A (zh) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | 嗒𠯤—3(2h)—酮衍生物 |
US11919869B2 (en) | 2021-10-29 | 2024-03-05 | Gilead Sciences, Inc. | CD73 compounds |
US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355010B1 (en) * | 1999-03-31 | 2002-03-12 | Coaxia, Inc. | Intravascular spinal perfusion and cooling for use during aortic surgery |
JP5279987B2 (ja) * | 2003-05-20 | 2013-09-04 | 味の素株式会社 | アミド誘導体 |
US20050239921A1 (en) * | 2004-04-27 | 2005-10-27 | Birmingham John N | Preparation of organic additive-treated, pyrogenic silica-encapsulated titanium dioxide particles |
UY32470A (es) * | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
WO2011023812A1 (en) | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
JP5579862B2 (ja) * | 2009-10-23 | 2014-08-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ミクロソームプロスタグランジンe2シンターゼ−1のインヒビター |
WO2013146970A1 (ja) * | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | 新規キノリン誘導体 |
EP3010913A4 (en) * | 2013-06-20 | 2016-12-07 | Novasaid Ab | Piperidinolbenzimidazole derivatives as MPGE-1 inhibitors |
AR102361A1 (es) | 2014-10-29 | 2017-02-22 | Lilly Co Eli | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 |
-
2015
- 2015-10-18 JO JOP/2015/0256A patent/JO3581B1/ar active
- 2015-10-19 AR ARP150103382A patent/AR102362A1/es unknown
- 2015-10-19 TW TW104134250A patent/TWI605039B/zh active
- 2015-10-22 PL PL15791432T patent/PL3230278T3/pl unknown
- 2015-10-22 LT LTEP15791432.6T patent/LT3230278T/lt unknown
- 2015-10-22 CN CN201580058595.9A patent/CN107074829B/zh active Active
- 2015-10-22 US US15/520,462 patent/US9962375B2/en active Active
- 2015-10-22 PT PT157914326T patent/PT3230278T/pt unknown
- 2015-10-22 SI SI201531036T patent/SI3230278T1/sl unknown
- 2015-10-22 DK DK15791432.6T patent/DK3230278T3/da active
- 2015-10-22 ES ES15791432T patent/ES2773439T3/es active Active
- 2015-10-22 KR KR1020177011303A patent/KR101898829B1/ko active IP Right Grant
- 2015-10-22 EA EA201790766A patent/EA032428B1/ru not_active IP Right Cessation
- 2015-10-22 WO PCT/US2015/056960 patent/WO2016069376A1/en active Application Filing
- 2015-10-22 EP EP15791432.6A patent/EP3230278B1/en active Active
- 2015-10-22 HU HUE15791432A patent/HUE047895T2/hu unknown
- 2015-10-22 RS RS20200015A patent/RS59783B1/sr unknown
- 2015-10-22 NZ NZ730724A patent/NZ730724A/en unknown
- 2015-10-22 AU AU2015339644A patent/AU2015339644B2/en active Active
- 2015-10-22 MX MX2017005659A patent/MX2017005659A/es active IP Right Grant
- 2015-10-22 JP JP2017522866A patent/JP6393830B2/ja active Active
- 2015-10-22 CA CA2963321A patent/CA2963321C/en active Active
-
2017
- 2017-03-29 ZA ZA2017/02198A patent/ZA201702198B/en unknown
- 2017-04-24 CL CL2017001017A patent/CL2017001017A1/es unknown
-
2018
- 2018-05-07 US US15/972,699 patent/US20180250282A1/en not_active Abandoned
-
2020
- 2020-01-29 CY CY20201100076T patent/CY1122534T1/el unknown
- 2020-02-11 HR HRP20200216TT patent/HRP20200216T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3581B1 (ar) | مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي | |
NZ730730A (en) | Novel carboxylic acid compounds useful for inhibiting microsomal prostaglandin e2 synthase-1 | |
PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
EA201691442A1 (ru) | N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2 | |
MY197698A (en) | Oxysterols and methods of use thereof | |
JO3466B1 (ar) | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 | |
PH12017500095A1 (en) | Imidazopyridazine compounds | |
MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
MX2016002718A (es) | Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc). | |
PH12014501712B1 (en) | Novel morpholinyl derivatives useful as mogat-2-inhibitors | |
PH12016501997B1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
TN2019000038A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
AU2016330503A8 (en) | Therapeutic compounds and methods of use thereof | |
MX2018015269A (es) | Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos. | |
MA39892A (fr) | Utilisation d'un acide dicarboxylique pour lutter contre la croissance de plantes holoparasites ou hémiparasites | |
PH12019502792A1 (en) | Tetrahydropyridopyrazine modulators of gpr6 |